The biopharma industry is experiencing a paradigm shift in the outsourcing of regulatory affairs operations. In particular, this trend is being adopted by biopharma companies with marketed and mature products who are seeking strategic partners to manage their post-approval regulatory operations. In addition, emerging companies do not have substantial global resources to manage large scale and costly regulatory activities, while expanding biopharma would rather refocus their resources and time in-house to core strategic regulatory activities.